$VTUS Phase 3 Results for Pair of GI Drugs Expected in First Two Quarters of 2012
publication date: Nov 16, 2011
Written by Mike Havrilla -- Ventrus Biosciences (NASDAQ:VTUS) is focused on the late-stage clinical development of two product candidates for the treatment of common gastrointestinal (GI) disorders (e.g. hemorrhoids, anal fissures and fecal incontinence). Below is a summary of the two lead product candidates for $VTUS.